Women with peripheral arterial disease (PAD) have more limited physical function than men but the mechanisms involved are not clear. We determined whether alterations in lipid components, such as decreased high-density lipoprotein cholesterol (HDL-C), are associated with worsening intermittent claudication (IC) in postmenopausal women with PAD. Our cross-sectional cohort study included 69 postmenopausal women with IC (Fontaine stage II). A treadmill test was used to measure initial claudication distance (ICD), absolute claudication distance (ACD), peak oxygen uptake, and ankle systolic blood pressure. High-density lipoprotein cholesterol correlated with ankle brachial index ([ABI]; R ¼ .29, P ¼ .019). No other lipid profile components were associated with exercise performance and hemodynamic measures. Among women with HDL-C <50 mg/dL (n ¼ 43), the median peak oxygen uptake level was significantly lower (P ¼ .021) relative to women with normal HDL-C >50 mg/dL (n ¼ 26). Lower HDL-C levels are associated with worse ABI and decreased peak oxygen uptake in postmenopausal women with PAD. Angiology 61(7) 698-704 ª The Author(s) 2010
Introduction
Patients with lower extremity peripheral arterial disease (PAD) often have dyslipidemia, 1,2 lower physical function, and faster functional decline than participants without PAD. 3, 4 The lipid abnormalities associated with lower extremity PAD include elevated total cholesterol and low-density lipoprotein cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C), and hypertriglyceridemia. 5 Lipids play a role in the initiation and progression of atherosclerosis in large vessels, 6, 7 a major cause of PAD. 5 Hypercholesterolemia may also contribute to increased damage at the microvessel level, as reflected by shorter walking distances and lower calf muscle hemoglobin oxygen saturation (StO 2 ) during exercise in patients limited by intermittent claudication (IC). 8 Women with PAD are more likely to present with uncontrolled cardiovascular risk factors, such as hypercholesterolemia, 9 and to have greater walking impairment than men with PAD. 10, 11 The mechanisms involved are not clear but could be linked to the lipid profile, or cigarette smoking that may directly decrease HDL-C. [12] [13] [14] In addition, data pertaining to traditional risk factors and their relation to objective measures of exercise performance are limited in patients with PAD, particularly in women. Therefore, we determined whether alterations in individual lipid components (eg, decreased HDL-C) are associated with worsening lower extremity IC in postmenopausal women with PAD.
Methods

Study Population
This cross-sectional cohort study included 69 postmenopausal women with PAD and stable symptoms of IC evaluated at the General Clinical Research Center in the University of Oklahoma Health Sciences Center. The participants were recruited from the vascular laboratory and clinics on campus, as well as from advertisements in local newspapers. All patients were classified as having Fontaine stage II PAD 5 defined by the following inclusion criteria: (a) a history of IC, (b) ambulation during a graded treadmill test limited by IC, 15 and (c) an ankle brachial index (ABI) at rest <0.90. 16 Participants were required to have cholesterol measures available. Patients were excluded for the following conditions: (a) absence of PAD, (b) inability to obtain an ABI measure due to noncompressible vessels, (c) asymptomatic PAD (Fontaine stage I), (d) rest pain PAD (Fontaine stage III), (e) exercise tolerance limited by factors other than IC (eg, severe coronary artery disease, dyspnea, poorly controlled blood pressure), and (f) active cancer, renal disease, or liver disease. All patients lived independently at home.
Patients were evaluated for dyslipidemia and were characterized as having dyslipidemia according to the published evidence-based guidelines for cardiovascular disease prevention in women 17 and consensus conference report from the American Diabetes Association and the American College of Cardiology. 18 Dyslipidemia was defined as having 1 or more of the following criteria: (1) LDL-C level >100 (2.6 mmol/L) or >70 mg/dL (1.8 mmol/L) if considered very high risk, (2) HDL-C level <50 mg/dL (1.3 mmol/L), (3) non-HDL-C (total cholesterol minus HDL-C) >130 (3.4 mmol/L) or >100 mg/dL (2.6 mmol/L) if considered very high risk, and/or (4) triglyceride level >150 mg/dL (1.7 mmol/L). Criteria for very high cardiovascular risk included established cardiovascular disease plus diabetes mellitus and/or smoking. 17 The institutional review board at the University of Oklahoma Health Sciences Center approved the procedures used in this study. Written informed consent was obtained from each participant before investigation.
Medical History
Demographic information, height, weight, cardiovascular risk factors, comorbid conditions, IC history, blood samples, and a list of current medications were obtained from a medical history and physical examination at the beginning of the study.
Walking Impairment Questionnaire
Self-reported ambulatory ability was assessed using a validated questionnaire that evaluates the ability to walk at various speeds and distances and to climb stairs in patients with PAD. 19 
Ankle Brachial Index Measurement
Prior to the treadmill test, ABI was determined by obtaining the ankle and brachial systolic blood pressures following 10 minutes of supine rest as previously described. 20 The test-retest intraclass reliability coefficient is R ¼ .96 for ABI. 15 Ankle systolic blood pressure was then obtained from the more severely diseased lower extremity by the Doppler ultrasound technique 1, 3, 5, 7, 9, 11, 13 , and 15 minutes after the progressive graded treadmill test. 21 The reduction in ankle systolic blood pressure following the treadmill test from the resting value was quantified by calculating the area under the curve (AUC) referred to as the ischemic window. 22 
Treadmill Test
Patients performed a progressive graded treadmill protocol (2 mph, 0% grade with 2% increase every 2 minutes) until maximal IC pain occurred. 15 The initial IC distance (ICD), the distance at which the patient first experienced pain, and the absolute ICD (ACD), the distance at which ambulation could not continue due to maximal pain, were both obtained and used to classify the severity of IC. Exercise capacity was quantified by measuring oxygen uptake at peak exercise with a Medical Graphics VO2000 metabolic system (Medical Graphics Inc, St Paul, Minnesota). Using these procedures, the test-retest intraclass reliability coefficient is R ¼ .89 for ICD, 15 R ¼ .93 for ACD, 15 and R ¼ .88 for peak oxygen uptake. 23 
Hemoglobin Oxygen Saturation (StO 2 ) of the Calf Musculature
Muscle oxygen saturation measurement provides clinically objective information regarding the severity of IC. 24 Calf muscle StO 2 was measured before and during exercise using a continuous wave, near-infrared spectroscopy (NIRS) (InSpectra model 325; Hutchinson Technology Inc, Hutchinson, Minnesota), as described before. 8 The noninvasive NIRS technique is a measure of the balance between local oxygen delivery and oxygen demand that quantifies the percentage of StO 2 in the microvasculature of the tissue below the NIRS probe, which is useful in assessing patients with PAD. 25, 26 In patients limited by IC, shorter ICD and ACD values are associated with reaching a minimum value in calf muscle StO 2 sooner during treadmill exercise and with having a delayed recovery in calf muscle StO 2 after exercise. 27 Calf muscle StO 2 at baseline was recorded after patients stood on the treadmill for 2 minutes to allow for equilibration. Following initiation of treadmill exercise, the StO 2 measure at the end of each minute was recorded, as well as the StO 2 value at the occurrence of ICD and ACD.
Calf Blood Flow
Calf blood flow was obtained during resting and under maximal hyperemic conditions in the more severely diseased leg using venous occlusion mercury strain gauge plethysmography, as previously described. 20 Briefly, resting calf blood flow was obtained after 10 minutes of supine rest, whereas maximal calf blood flow was obtained after patients stood and performed heel rises for as long as they could tolerate while a blood pressure cuff placed above the knee was inflated to 300 mm Hg. The test-retest intraclass reliability coefficient is R ¼ .86 for calf blood flow. 28 
Statistical Analyses
Between-group comparisons were made using a Wilcoxon rank sum test when comparing median values and a Chi-square or Fisher exact test, in the presence of low expected cell counts, when comparing proportions. The association between 2 continuous measures was quantified using a partial Spearman rank correlation coefficient with adjustment for age and body mass index (BMI). Linear regression modeling was used to adjust between-group comparisons for the potential confounding effects of age and BMI. Linear regression modeling assumptions were assessed using plots of residual values. A P of .05 was considered significant. Analyses were performed using SAS version 9.1.3 Service Pack 4 for Windows (SAS Institute Inc, Cary, North Carolina).
Results
Among the 69 women included in this analysis, 15 (22%) were classified as having a very high cardiovascular risk (criteria for very high risk include previous history of myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass surgery, transitory ischemic attack, stroke, carotid stent, or carotid endarterectomy) plus diabetes and/or current smoking, and only 45 (67%) were receiving lipid-lowering treatment. Dyslipidemia was highly prevalent (88%) in the total cohort, regardless of whether the women were on lipid-lowering therapy (87%) or not (91%). Of the 61 women with dyslipidemia, 21 (34%) were not on lipid lowering treatment. Table 1 summarizes the distribution of lipid profile values among the participants. Table 2 summarizes the association between individual components of the lipid profile and exercise performance, and peripheral hemodynamic measures after adjustment for age and BMI. High-density lipoprotein cholesterol was positively correlated with ABI (P ¼ .019), and there is a trend for a positive correlation with ACD and ICD (P ¼ .11 for each), although not significant. None of the other lipid measures were significantly associated with exercise performance and peripheral hemodynamic measures.
To further explore the association between HDL-C and exercise performance, the participants were divided according to HDL-C status (HDL-C <50 vs HDL-C !50 mg/dL [1.3 mmol/L]). All participants with HDL-C <50 mg/dL (1.3 mmol/L; n ¼ 43) were classified as having dyslipidemia compared with 18 (69%) of the 26 participants with HDL-C !50 mg/dL (1.3 mmol/L; Table 3 ). Women with HDL-C <50 mg/ dL (1.3 mmol/L) had a higher prevalence of coronary artery disease compared with women with HDL-C ! 50 mg/dL (1.3 mmol/L; 42% vs 15%, P ¼ .022), and had a trend for a higher prevalence of diabetes (P ¼ .11), although not significant. The median peak oxygen uptake level was significantly lower among women with HDL-C <50 mg/dL (1.3 mmol/L; P ¼ .021) and there was a trend for the median ACD to be lower as well (P ¼ .11), although not significant (Table 4 ). Based on regression modeling, the difference in peak oxygen uptake levels between women with HDL-C <50 mg/dL and women with HDL-C !50 mg/dL (1.3 mmol/L) remained significant after adjusting for age and BMI (mean peak oxygen uptake levels 2.03 mLÁkg À1 Ámin À1 lower for women with HDL-C <50 mg/dL (1.3 mmol/L), 95% CI: 0.14 to 3.92 mL . kg -1 Ámin -1 , P ¼ .036).
Discussion
Our major findings were that higher HDL-C levels were positively associated with ABI and, conversely, women with PAD and low HDL-C had poorer exercise capacity as reflected by lower peak oxygen uptake and a trend toward shorter ACD than women with normal HDL-C. Our findings are supported by previous studies which found that HDL-C was significantly associated with incident symptomatic PAD in women followed for over 12 years. 1 Interestingly, this association has not been observed in cohorts conformed mainly by male patients. 29 High-density lipoprotein cholesterol levels have also been correlated with lower extremity function measured by knee extension torque and walking speed. 30 Higher HDL-C has been associated with better functional performance among elderly participants 31 and low HDL-C has been linked with disease severity in early-onset PAD in young participants. 32 Collectively, these data suggest that there may be a direct relation between an altered lipid profile and walking capacity.
Physiologic mechanisms for the association between unfavorable HDL-C and impaired exercise performance include a potentially greater atherosclerotic compromise in the microvasculature. High-density lipoprotein exerts its atheroprotective function by favoring reverse cholesterol transport. 33 In addition, HDL-C appears to reduce acute vascular inflammation, exert direct nitric oxide-mediated vasodilatory effects, and improve endothelial function. 34 Low HDL-C has been associated with higher blood viscosity, 35 which may be linked to significant deterioration of blood flow properties, and higher HDL-C levels may ameliorate impaired microvascular blood flow. Another possibility is that HDL-C has also been shown to favor angiogenesis in human cell models 36 and murine ischemic hind limb models. 37 In speculation, higher HDL levels may be linked to collateral vessel formation that favors Abbreviations: BMI, body mass index; ABI, ankle brachial index; ICD, initial claudication distance; ACD, absolute claudication distance; StO 2 , hemoglobin oxygen saturation of the calf musculature; LDL-C: low density lipoproteins cholesterol; HDL-C: high density lipoproteins cholesterol.
blood flow to the affected limb. All of these possible physiological mechanisms may explain the better exercise performance, as measured by peak oxygen uptake, in patients with higher levels of HDL-C. However, further studies are required to evaluate these possibilities.
Other important findings of our study included the high prevalence of untreated dyslipidemia in our cohort of women with PAD. Although nearly 90% of the women in this investigation were dyslipidemic, only 67% were medically managed for this condition and 34% were not receiving any treatment at all. Furthermore, of the patients on lipid-lowering treatment, many may have been receiving suboptimal management. These findings compare favorably with previous reports that show diagnosis and treatment of dyslipidemia is often suboptimal in patients with PAD. 38, 39 Dyslipidemia is often treated with lipid-lowering agents, such as statins, and in patients with IC its use has been associated with superior leg functioning 40 and improved pain-free walking distance and activity. 41 The clinical significance is that reduced HDL-C has been associated with poor cardiovascular outcomes and effective treatment of dyslipidemia should be offered to all patients with PAD to decrease subsequent risk of myocardial infarction, stroke, and vascular death. [42] [43] [44] Lowering LDL-C may be the single most beneficial strategy to decrease cardiovascular events; strategies that only increase HDL-C may not result in a significant decrease in cardiovascular disease or death. 45 Early recognition, risk factor modification, and lipid-modifying therapy substantially reduce morbidity and mortality in this patient population, regardless of the initial cholesterol level. 44 Limitations of this study include small sample size. The cross-sectional design of the study does not allow us to clarify any causeÀeffect mechanism. Further studies are required to confirm the association of HDL-C levels and objective markers of walking performance and to evaluate whether management of the dyslipidemic profile improves walking ability and therefore clinical cardiovascular endpoints.
Conclusions
Lower HDL-C levels are associated with lower ABI and decreased peak oxygen uptake in postmenopausal women with PAD. The clinical and treatment implications of this finding need to be further investigated.
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